Valeo Spacer System and Valeo II Interbody Fusion Device System
Device Facts
| Record ID | K143518 |
|---|---|
| Device Name | Valeo Spacer System and Valeo II Interbody Fusion Device System |
| Applicant | Amedica Corp. |
| Product Code | MAX · Orthopedic |
| Decision Date | Oct 2, 2015 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 888.3080 |
| Device Class | Class 2 |
| Attributes | Therapeutic, Real-World Evidence |
Real-World Evidence
| Submission | Device | Sponsor | RWD Sources | RWE Use Summary | Key Tags |
|---|---|---|---|---|---|
| K143518 · Oct 2, 2015 | Valeo Spacer System and Valeo II Interbody Fusion Device System | Amedica Corp. | Clinical literature review | A clinical literature review was conducted to assess the safety and risks associated with using the Valeo Spacer System and Valeo II Interbody Fusion Device System with allograft in lumbar fusion procedures, supporting the expansion of indications. | Literature review; Lumbar fusion; Allograft; Safety assessment |
Clinical Evidence
| Study Design | Population | Comparator | Key Endpoints |
|---|---|---|---|
| Clinical literature review; Literature review | Patients undergoing lumbar fusion procedures | Not applicable for this study | Safety and risks associated with the use of the device with allograft in the lumbar spine |
Indications for Use
Valeo® Spacer System and Valeo II™ Interbody Fusion Device System -Cervical are indicated for use in skeletally mature patients with degenerative disc disease (DDD) of the cervical spine with accompanying radicular symptoms at one disc level or two contiguous levels. DDD is defined as discogenic pain with degeneration of the disc confirmed by patient history and radiographic studies. Valeo® Spacer System-C and Valeo II™ Interbody Fusion Device System -Cervical are used to facilitate intervertebral body fusion in the cervical spine and are placed via an anterior approach from the C2-C3 disc space to the C7-T1 disc space using autograft or allogenic bone graft comprised of cancellous and/or corticocancellous bone graft. Valeo® Spacer System-C and Valeo II™ Interbody Fusion Device System -Cervical are to be used with supplemental fixation. Patients should have at least six (6) weeks of non-operative treatment prior to treatment with an intervertebral cage. Valeo® Spacer System-L and Valeo II™ Interbody Fusion Device System - Lumbar are indicated for use with autogenous bone graft and/or allogenic bone graft comprised of cancellous bone graft in patients with degenerative disc disease (DDD) at one level or two contiguous levels from L2 to S1. DDD is defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies. The DDD patients may also have up to Grade I spondylolisthesis at the involved level(s). Valeo® Spacer System-L and Valeo II™ Interbody Fusion Device System – Lumbar are intended to be used with supplemental spinal fixation systems, such as Preference Pedicle Screw System. Patients should be skeletally mature and have six months of non-operative therapy prior to treatment with an intervertebral cage.
Device Story
Hollow intervertebral body spacers; convex, bullet-nose design; axial void for bone graft (autograft/allograft); angular teeth for endplate grip/expulsion resistance. Used in spinal fusion surgery; placed via anterior approach (cervical) or lumbar approach. Operated by surgeons in clinical/OR settings. Provides structural support to facilitate intervertebral fusion; used with supplemental fixation systems. Benefits patients by stabilizing spinal segments and promoting fusion in DDD cases.
Clinical Evidence
No clinical trials performed. Evidence based on a comprehensive clinical literature review assessing safety of using the device with allograft in lumbar fusion procedures. Review concluded no additional risks compared to predicate devices.
Technological Characteristics
Material: Si3N4 (silicon nitride) ceramic. Design: Hollow spacer with axial void, convex bullet-nose, and angular teeth for fixation. Provided sterile. No software or electronic components.
Indications for Use
Indicated for skeletally mature patients with degenerative disc disease (DDD) of the cervical spine (C2-T1) or lumbar spine (L2-S1) at one or two contiguous levels. Cervical patients must have radicular symptoms; lumbar patients may have up to Grade I spondylolisthesis. Requires 6 weeks (cervical) or 6 months (lumbar) of non-operative therapy. Must be used with supplemental fixation and autograft or allogenic bone graft.
Regulatory Classification
Identification
An intervertebral body fusion device is an implanted single or multiple component spinal device made from a variety of materials, including titanium and polymers. The device is inserted into the intervertebral body space of the cervical or lumbosacral spine, and is intended for intervertebral body fusion.
Special Controls
*Classification.* (1) Class II (special controls) for intervertebral body fusion devices that contain bone grafting material. The special control is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.” See § 888.1(e) for the availability of this guidance document.(2) Class III (premarket approval) for intervertebral body fusion devices that include any therapeutic biologic (e.g., bone morphogenic protein). Intervertebral body fusion devices that contain any therapeutic biologic require premarket approval. (c) *Date premarket approval application (PMA) or notice of product development protocol (PDP) is required.* Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.
Predicate Devices
Reference Devices
- Preference Pedicle Screw System